MedPath

A randomized, double-blind, split-faced study comparing A.I. Clearing Treatment with 0.1% adapalene versus 0.1% adapalene in treatment of mild to moderate degree acne vulgaris

Phase 2
Conditions
mild to moderate degree acne vulgaris
acne vulgaris
acne
adapalene
glycolic acid
salicylic acid
gluconolactone
licochalcone A
moisture
A.I. Clearing Treatment
Registration Number
TCTR20171031005
Lead Sponsor
Beiersdorf (Thailand) Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
25
Inclusion Criteria

1. Male or female, 18-40 years old
2. Mild to moderate acne vulgaris by Acne Consensus Conference (ACC) criteria

Exclusion Criteria

1. previous phototherapy/laser within 4 weeks or use topical/systemic for treat acne within 2
2. who has other skin lesion or skin disease in study area
3. pregnancy or lactation
4. allergy to adapalene, glycolic acid, salicylic acid, gluconolactone, licochalcone A
5. immunocompromised host
6. psychiatric problem

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
inflammatory lesions of acne 0, 1, 2, 4 weeks counting
Secondary Outcome Measures
NameTimeMethod
erythema (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),scale (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),burning (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),itching (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),transpeidermal water loss 0, 1, 2, 4 weeks Tewameter®,skin hydration 0, 1, 2, 4 weeks Corneometer®,acne grading 0, 1, 2, 4 weeks Acne Consensus Conference (ACC),radiance visual analog scale 0, 1, 2, 4 weeks visual analog scale (VAS) for degree of sleepiness,Investigator’s Global Assessment Acne (IGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5),Patient’s Global Assessment Acne (PGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5)
© Copyright 2025. All Rights Reserved by MedPath